JP2023129433A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023129433A5 JP2023129433A5 JP2023106715A JP2023106715A JP2023129433A5 JP 2023129433 A5 JP2023129433 A5 JP 2023129433A5 JP 2023106715 A JP2023106715 A JP 2023106715A JP 2023106715 A JP2023106715 A JP 2023106715A JP 2023129433 A5 JP2023129433 A5 JP 2023129433A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody molecule
- seq
- nos
- pharmaceutical composition
- treg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025116576A JP2025157343A (ja) | 2017-07-26 | 2025-07-10 | 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1712032.0A GB201712032D0 (en) | 2017-07-26 | 2017-07-26 | Antibodies and uses thereof |
| GB1712032.0 | 2017-07-26 | ||
| PCT/EP2018/070359 WO2019020774A2 (en) | 2017-07-26 | 2018-07-26 | NOVEL ANTIBODIES AND COMBINED USE OF ANTIBODY THAT INDUCES TREG DEPLOYMENT AND AN IMMUNOSTIMULATOR ANTIBODY |
| JP2020526685A JP7458973B2 (ja) | 2017-07-26 | 2018-07-26 | 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526685A Division JP7458973B2 (ja) | 2017-07-26 | 2018-07-26 | 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025116576A Division JP2025157343A (ja) | 2017-07-26 | 2025-07-10 | 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023129433A JP2023129433A (ja) | 2023-09-14 |
| JP2023129433A5 true JP2023129433A5 (https=) | 2024-06-20 |
Family
ID=59771732
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526685A Active JP7458973B2 (ja) | 2017-07-26 | 2018-07-26 | 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 |
| JP2023106715A Pending JP2023129433A (ja) | 2017-07-26 | 2023-06-29 | 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 |
| JP2025116576A Pending JP2025157343A (ja) | 2017-07-26 | 2025-07-10 | 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526685A Active JP7458973B2 (ja) | 2017-07-26 | 2018-07-26 | 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025116576A Pending JP2025157343A (ja) | 2017-07-26 | 2025-07-10 | 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11447549B2 (https=) |
| EP (1) | EP3658587A2 (https=) |
| JP (3) | JP7458973B2 (https=) |
| CN (1) | CN111108124B (https=) |
| AU (1) | AU2018305209B2 (https=) |
| CA (1) | CA3070290A1 (https=) |
| GB (1) | GB201712032D0 (https=) |
| WO (1) | WO2019020774A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190017735A (ko) * | 2016-04-07 | 2019-02-20 | 캔써 리서치 테크놀로지 리미티드 | 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체 |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| CN112739339B (zh) | 2018-07-23 | 2024-12-27 | 海德堡医药研究有限责任公司 | 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途 |
| ES2903440T3 (es) * | 2018-09-13 | 2022-04-01 | Euroimmun Medizinische Labordiagnostika Ag | Procedimiento y dispositivo para registrar y visualizar una imagen de inmunofluorescencia de una muestra biológica |
| NZ781538A (en) | 2019-04-24 | 2025-12-19 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| US20210038684A1 (en) * | 2019-06-11 | 2021-02-11 | Alkermes Pharma Ireland Limited | Compositions and Methods for Cancer Immunotherapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015237864B2 (en) * | 2014-03-24 | 2020-12-03 | Cancer Research Technology Limited | Modified antibodies containing modified IgG2 domains which elicit agonist or antagonistic properties and use thereof |
| WO2015188047A1 (en) * | 2014-06-06 | 2015-12-10 | University Of Maryland, Baltimore | ANTI-CD-137 MONOCLONAL ANTIBODIES WITH DISTINCT FcγR BINDING ABILITIES FOR TREATMENT OF CANCER OR AUTOIMMUNITY |
| EP3183269A2 (en) * | 2014-08-22 | 2017-06-28 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| JP6180663B2 (ja) | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| RS60614B1 (sr) | 2015-03-23 | 2020-08-31 | Jounce Therapeutics Inc | Antitela za icos |
| MX2017015937A (es) * | 2015-06-08 | 2018-12-11 | Genentech Inc | Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1. |
| GB201519481D0 (en) * | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
| KR20190017735A (ko) | 2016-04-07 | 2019-02-20 | 캔써 리서치 테크놀로지 리미티드 | 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체 |
| BR112019025913A2 (pt) | 2017-06-09 | 2020-06-30 | Glaxosmithkline Intellectual Property Development Limited | métodos para tratar câncer em um paciente em necesssidade do mesmo e para produzir um anticorpo, anticorpo anti-icos ou fragmento de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou fragmento de ligação ao antígeno do mesmo, uso de um anticorpo anti-icos ou porção de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou porção de ligação ao antígeno do mesmo na fabricação de um medicamento, polinucleotídeo que codifica um anticorpo, vetor, e, célula hospedeira. |
-
2017
- 2017-07-26 GB GBGB1712032.0A patent/GB201712032D0/en not_active Ceased
-
2018
- 2018-07-26 EP EP18753084.5A patent/EP3658587A2/en active Pending
- 2018-07-26 CA CA3070290A patent/CA3070290A1/en active Pending
- 2018-07-26 WO PCT/EP2018/070359 patent/WO2019020774A2/en not_active Ceased
- 2018-07-26 US US16/633,740 patent/US11447549B2/en active Active
- 2018-07-26 AU AU2018305209A patent/AU2018305209B2/en active Active
- 2018-07-26 CN CN201880050094.XA patent/CN111108124B/zh active Active
- 2018-07-26 JP JP2020526685A patent/JP7458973B2/ja active Active
-
2022
- 2022-08-11 US US17/819,234 patent/US20230058227A1/en active Pending
-
2023
- 2023-06-29 JP JP2023106715A patent/JP2023129433A/ja active Pending
-
2025
- 2025-07-10 JP JP2025116576A patent/JP2025157343A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023129433A5 (https=) | ||
| JP2020504723A5 (https=) | ||
| JP2022061993A5 (https=) | ||
| JP2020520665A5 (https=) | ||
| JP2020103301A5 (https=) | ||
| JP2021516976A5 (https=) | ||
| JP2024167313A5 (https=) | ||
| JP2021515566A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| JP2021516973A5 (https=) | ||
| JP2021501162A5 (https=) | ||
| JP2021515568A5 (https=) | ||
| HRP20251181T1 (hr) | Protutijela na protein gprc5d, bispecifične molekule koje vezuju antigen i koje vezuju gprc5d i cd3 te njihove primjene | |
| JP2019502676A5 (https=) | ||
| JP2019511212A5 (https=) | ||
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| JP2014522850A5 (https=) | ||
| JP2024515591A5 (https=) | ||
| JP2024119853A5 (https=) | ||
| JP2010531140A5 (https=) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| JP2019534710A5 (https=) | ||
| JP2024541680A5 (https=) | ||
| JP2022553922A5 (https=) | ||
| JP2020515577A5 (https=) |